HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
First and only PARP inhibitor to improve invasive disease-free survival in patients
The Congress was held on June, 20-21, 2022 in Berlin, Germany
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Subscribe To Our Newsletter & Stay Updated
